An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

S Drożdżal, J Rosik, K Lechowicz, F Machaj… - Drug Resistance …, 2021 - Elsevier
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

[HTML][HTML] The development of COVID-19 treatment

Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

B Killingley, AJ Mann, M Kalinova, A Boyers… - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …

[HTML][HTML] Early remdesivir to prevent progression to severe Covid-19 in outpatients

RL Gottlieb, CE Vaca, R Paredes, J Mera… - … England Journal of …, 2022 - Mass Medical Soc
Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)

A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …

[HTML][HTML] Global pandemics interconnected—obesity, impaired metabolic health and COVID-19

N Stefan, AL Birkenfeld, MB Schulze - Nature Reviews Endocrinology, 2021 - nature.com
Obesity and impaired metabolic health are established risk factors for the non-
communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease …

Severe covid-19 pneumonia: pathogenesis and clinical management

AH Attaway, RG Scheraga, A Bhimraj, M Biehl… - bmj, 2021 - bmj.com
Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …

COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment

A Parasher - Postgraduate medical journal, 2021 - academic.oup.com
Background The severe acute respiratory syndrome (SARS) coronavirus-2 is a novel
coronavirus belonging to the family Coronaviridae and is now known to be responsible for …

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 …

PD Monk, RJ Marsden, VJ Tear, J Brookes… - The Lancet …, 2021 - thelancet.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
carries a substantial risk of severe and prolonged illness; treatment options are currently …

COVID-19: Discovery, diagnostics and drug development

T Asselah, D Durantel, E Pasmant, G Lau… - Journal of …, 2021 - Elsevier
Summary Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019,
and has since become a pandemic. Groups from China identified and sequenced the virus …